NUVB beat EPS expectations by 6.98%
Nov 03, 2025, 11:35 PM
0.00%
What does NUVB do
Nuvation Bio, based in San Francisco, develops novel oncology therapies and has 159 employees. Its clinical portfolio includes candidates like taletrectinib and safusidenib, targeting specific cancer mutations.
Nuvation Bio (NUVB) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Nuvation Bio's actual EPS was -$0.16, beating the estimate of -$0.17 per share, resulting in a 6.98% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.